title: The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.
abstract: Replication-competent oncolytic viruses hold great potential for the clinical treatment of many cancers. Importantly, many oncolytic virus candidates, such as reovirus and myxoma virus, preferentially infect cancer cells bearing abnormal cellular signaling pathways. Reovirus and myxoma virus are highly responsive to activated Ras and Akt signaling pathways, respectively, for their specificity for viral oncolysis. However, considering the complexity of cancer cell populations, it is possible that other tumor-specific signaling pathways may also contribute to viral discrimination between normal versus cancer cells. Because carcinogenesis is a multistep process involving the accumulation of both oncogene activations and the inactivation of tumor suppressor genes, we speculated that not only oncogenes but also tumor suppressor genes may have an important role in determining the tropism of these viruses for cancer cells. It has been previously shown that many cellular tumor suppressor genes, such as p53, ATM and Rb, are important for maintaining genomic stability; dysfunction of these tumor suppressors may disrupt intact cellular antiviral activity due to the accumulation of genomic instability or due to interference with apoptotic signaling. Therefore, we speculated that cells with dysfunctional tumor suppressors may display enhanced susceptibility to challenge with these oncolytic viruses, as previously seen with adenovirus. We report here that both reovirus and myxoma virus preferentially infect cancer cells bearing dysfunctional or deleted p53, ATM and Rb tumor suppressor genes compared to cells retaining normal counterparts of these genes. Thus, oncolysis by these viruses may be influenced by both oncogenic activation and tumor suppressor status.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Kim
authors.forename: C T
authors.initials: CT
authors.lastname: Williamson
authors.forename: J
authors.initials: J
authors.lastname: Prudhomme
authors.forename: D G
authors.initials: DG
authors.lastname: Bebb
authors.forename: K
authors.initials: K
authors.lastname: Riabowol
authors.forename: P W K
authors.initials: PW
authors.lastname: Lee
authors.forename: S P
authors.initials: SP
authors.lastname: Lees-Miller
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: M M
authors.initials: MM
authors.lastname: Rahman
authors.forename: G
authors.initials: G
authors.lastname: McFadden
authors.forename: R N
authors.initials: RN
authors.lastname: Johnston
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins / Q000235:genetics; D045744:Cell Line, Tumor; D004268:DNA-Binding Proteins / Q000172:deficiency / Q000235:genetics; D017353:Gene Deletion; D055785:Gene Knockdown Techniques; D016147:Genes, Tumor Suppressor; D006801:Humans; D051379:Mice; D009233:Myxoma virus / Q000502:physiology*; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology / Q000821:virology*; D050504:Oncolytic Viruses / Q000502:physiology*; D017346:Protein Serine-Threonine Kinases / Q000172:deficiency / Q000235:genetics; D012087:Reoviridae / Q000502:physiology*; D016160:Retinoblastoma Protein / Q000172:deficiency / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000172:deficiency / Q000235:genetics; D056189:Viral Tropism
chemical_list: D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; C576325:Atm protein, mouse; D017346:Protein Serine-Threonine Kinases
references.citation: Mutat Res. 2002 Mar;511(1):45-62
references.pmid: 11906841
references.citation: Cold Spring Harb Symp Quant Biol. 2005;70:99-109
references.pmid: 16869743
references.citation: Cancer Res. 2007 Sep 15;67(18):8818-27
references.pmid: 17875723
references.citation: Semin Cancer Biol. 2003 Aug;13(4):267-73
references.pmid: 14563121
references.citation: J Virol. 2003 May;77(10):5877-88
references.pmid: 12719581
references.citation: Nat Rev Microbiol. 2005 Mar;3(3):201-13
references.pmid: 15738948
references.citation: Cell Cycle. 2004 Aug;3(8):1043-5
references.pmid: 15254403
references.citation: Science. 1996 Oct 18;274(5286):373-6
references.pmid: 8832876
references.citation: Oncogene. 1999 Mar 18;18(11):1935-44
references.pmid: 10208415
references.citation: J Virol. 1996 Jan;70(1):612-6
references.pmid: 8523580
references.citation: Oncogene. 2006 May 18;25(21):3006-22
references.pmid: 16501611
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4640-5
references.pmid: 16537421
references.citation: Cancer Cell. 2004 Dec;6(6):611-23
references.pmid: 15607965
references.citation: J Exp Med. 2008 Aug 4;205(8):1929-38
references.pmid: 18663127
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11099-104
references.pmid: 15263068
references.citation: J Virol. 2004 Nov;78(22):12243-51
references.pmid: 15507611
references.citation: Nature. 2003 Jul 31;424(6948):516-23
references.pmid: 12872134
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):7127-37
references.pmid: 18981012
references.citation: J Virol. 1978 Nov;28(2):444-9
references.pmid: 214572
references.citation: Expert Opin Biol Ther. 2007 Sep;7(9):1415-25
references.pmid: 17727330
references.citation: Oncogene. 2007 Jun 14;26(28):4124-34
references.pmid: 17213803
references.citation: Oncogene. 2005 Nov 21;24(52):7817-9
references.pmid: 16299540
references.citation: Leuk Res. 2006 Apr;30(4):449-57
references.pmid: 16183118
references.citation: EMBO J. 1998 Jun 15;17(12):3351-62
references.pmid: 9628872
references.citation: Cancer Gene Ther. 2010 Jan;17(1):69-70
references.pmid: 19590528
references.citation: Cancer Res. 2005 Nov 1;65(21):9982-9990
references.pmid: 16267023
references.citation: Mol Ther. 2008 Mar;16(3):627-32
references.pmid: 18253152
references.citation: Cancer Gene Ther. 2009 Apr;16(4):382
references.pmid: 18949012
references.citation: Arch Virol. 1977;54(4):307-15
references.pmid: 562142
references.citation: Virology. 1993 Nov;197(1):405-11
references.pmid: 8212574
references.citation: J Natl Cancer Inst. 1974 Aug;53(2):347-60
references.pmid: 4135597
references.citation: Blood. 2002 Dec 1;100(12):4146-53
references.pmid: 12393565
references.citation: Science. 1998 Nov 13;282(5392):1332-4
references.pmid: 9812900
references.citation: J Virol. 2009 Jun;83(11):5928-32
references.pmid: 19297474
references.citation: J Biol Chem. 2003 Mar 14;278(11):9309-17
references.pmid: 12645530
references.citation: Drug Discov Today. 2005 Jun 15;10(12):847-55
references.pmid: 15970267
references.citation: Leukemia. 2009 Dec;23(12):2313-7
references.pmid: 19865109
references.citation: Nature. 1994 Sep 1;371(6492):21-2
references.pmid: 8072521
references.citation: Oncogene. 2006 Mar 9;25(10):1509-20
references.pmid: 16247442
references.citation: Mol Ther. 2008 Jan;16(1):52-9
references.pmid: 17998900
references.citation: Blood. 2009 Mar 26;113(13):3059-69
references.pmid: 18984860
references.citation: Hepatology. 2008 Apr;47(4):1136-49
references.pmid: 18220274